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Background: Limited data define what constitutes a minimal clinically important difference (MCID) on the EuroQol
5-Dimension (EQ-5D) health status index in persons with multiple sclerosis (PwMS). We sought to estimate the
MCID for the EQ-5D health index in North American PwMS.
Methods: PwMS completing the Patient Determined Disease Steps (PDDS) scale, 12-Item Multiple Sclerosis Walking
Scale (MSWS-12) and EQ-5D as part of the North American Research Committee on Multiple Sclerosis (NARCOMS)
registry’s spring 2011 update and supplemental survey were included in this retrospective, cross-sectional study.
Distribution-based (standard error of measurement [SEM], 0.50 standard deviation [SD] and 0.33 SD unit) approaches
were used to estimate a range of MCIDs for the EQ-5D based upon disease severity groups determined by the
PDDS and MSWS-12 tertiles.
Results: A total of 3,044 participants were included. Moderately strong correlations between the EQ-5D and the
PDDS and MSWS-12 were observed (Spearman’s r = −0.56 and −0.59, respectively, p < 0.0001 for both). MCID
estimates based on PDDS score categories ranged from 0.065-0.158 (SEMs), 0.059-0.142 (0.50 SDs) and 0.039-0.095
(0.33 SDs). MCID estimates as measured by MSWS-12 tertile categories ranged from 0.068-0.098 (SEMs), 0.061-0.088
(0.50 SDs), and 0.041-0.059 (0.33 SDs). Across both the PDDS and tertiles of MSWS-12, MCID estimates tended to be
larger as disease severity worsened. Mean weighted MCID estimates ranged from 0.05-0.084 for both the PDDS and
MSWS-12 tertiles.
Conclusion: MCID estimates for the EQ-5D in PwMS were within the range of estimates seen for other disease
states and appeared to be larger in those reporting more severe disease.
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differenceIntroduction
Multiple sclerosis (MS) has long been known to negatively
impact health-related quality of life (HRQoL) [1-3]. For this
reason, clinical studies have increasingly utilized validated
HRQoL measures to evaluate the effect of treatment or the
impact of disease progression on HRQoL in persons with
MS (PwMS) [4-6]. The Euro-Qol 5-Dimension (EQ-5D), a
generic health status index score [7,8], is one such
measure; however, interpretation of the EQ-5D in* Correspondence: craig.coleman@hhchealth.org
1Department of Pharmacy Practice, University of Connecticut School of
Pharmacy, Storrs, CT, USA
2Hartford Hospital Evidence-Based Practice Center, Hartford, CT, USA
Full list of author information is available at the end of the article
© 2014 Kohn et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.PwMS is hampered by a paucity of information regarding
what constitutes a minimally important clinical improve-
ment in score in this population. The purpose of this
study was to estimate the minimal clinically important
difference (MCID), or smallest difference in score PwMS
from North America perceive as being both beneficial and
nontrivial [9].Methods
We used data from the North American Research
Committee on Multiple Sclerosis (NARCOMS) registry
to conduct this retrospective, cross-sectional analysis
[10]. NARCOMS gathers self-reported patient datatd. This is an Open Access article distributed under the terms of the Creative
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trants. In 2010, NARCOMS, in conjunction with Acorda
Therapeutics, Inc., sent a supplemental questionnaire to a
sample of 4,389 NARCOMS registrants reporting a
Patient-Determined Disease Step (PDDS) score ≤7 to
collect additional data on patient perceptions of
HRQoL using the EQ-5D, 3-level (3 L) descriptive
system and walking using the 12-item Multiple Sclerosis
Walking Scale (MSWS-12). The supplemental survey
was sent about one month after the close of the update
survey.
The collection and research use of NARCOMS data is
approved by the Institutional Review Board (IRB) at the
University of Alabama at Birmingham. Approval was
obtained from the same IRB for the acquisition of the
additional data via the supplemental questionnaire. The
secondary analyses reported here were reviewed and
approved by the IRB at Hartford Hospital and conducted
with de-identified datasets.
PwMS who completed the EQ-5D, PDDS and MSWS-12
as part of the NARCOMS update and supplemental
surveys during spring 2010 were included in this study.
The EQ-5D-3 L consists of five descriptive questions con-
cerning five domains of HRQoL (mobility, self-care, usual
activities, pain/discomfort, anxiety/depression) each with 3-
levels of response (no, some/moderate or unable/extreme)
with participants’ pattern of responses used to derive health
status index scores. US-specific health status index scores
between 1.0 and −0.11 (on a scale where 1.0 = perfect
health and 0.0 = death, negative values suggest health states
worse than death) were derived using the scoring algorithm
developed in a study of a general US population [7].
Disease severity in PwMS was evaluated using the
PDDS, as the Kurtzke Expanded Disability Status Scale
(EDSS) and other clinician-based tools (signs, symptoms
and medical examination results) are not available in the
NARCOMS registry. The PDDS is a patient-reported
measure that is scored ordinally from 0 (no disability) to
8 (bedbound) [11]. It has been shown to correlate well
with the neurologist scored EDSS (r = 0.78; p = 0.0001)
[12]; and both measures have been used by clinicians
and researchers to assess MS-related disease severity
and progression.
PwMS also completed the MSWS-12, a validated,
patient-reported outcome measure of walking impair-
ment that consists of 12 questions with five possible
responses ranging from 1 (not at all) to 5 (extremely)
[13]. Each question represents a different aspect of walk-
ing function and quality, including walking speed, ability
to run, ability to climb and descend stairs, ability to
stand, balance, endurance, smoothness of gait, need for
support (indoors and outdoors), and concentration
required. The possible scores for this measure range from
12–60, and were converted to scores ranging to 0–100 foreasier interpretation, with higher scores representing
greater walking disability [13]. The MSWS-12 is the only
measure of walking ability reported in the NARCOMS
registry and is strongly correlated with both the PDDS (r =
0.80; p < 0.01) and EDSS (r = 0.73; p < 0.01) (since both the
PDDS and EDSS focus on mobility in the middle of their
scales) [12].
Since no suitable anchor was available in our NAR-
COMS dataset, multiple distribution-based approaches
were used to estimate MCIDs for the EQ-5D in this NAR-
COMS cohort. Consistent with prior studies, we used the
following distribution-based approaches: (1) the standard
error of measurement (SEM), (2) 0.5 * standard deviation
(SD) and (3) 0.33 * SD [9,14-19]. The SEM describes the
variability between an individual’s observed score and the
true score and is calculated as the SD of the measure
multiplied by the square root of 1 minus its reliability
coefficient [9,14]. For this analysis, we used Cronbach’s
alpha as the measure of reliability of the EQ-5D when
calculating the SEM. Our estimate of Cronbach’s alpha in
this NARCOMS population was 0.69, which is consistent
with estimates reported in prior studies [19].
Correlations between the PDDS, MSWS-12 and the
EQ-5D were assessed using Spearman’s rho (r), with a
coefficient ≥0.40 suggesting an adequate correlation. We
used the PDDS to define disease severity in PwMS (using
the ordinal values from 0–8) and the MSWS-12 tertiles
(with scores of 0 – 33 representing mild walking im-
pairment; 34 – 67 as moderate walking impairment;
and 68 – 100 representing severe walking impairment) to
grouppatients into walking impairment categories. Subse-
quently, we applied the above-mentioned distribution-based
approaches to each category. Resulting MCID estimates
were summarized as ranges, and a mean MCID across
categories, weighted by sample size, was calculated for each
questionnaire.
Descriptive statistics including percentages for categorical
data; and medians/ranges and means/SDs for ordinal/
continuous data are reported. All data analyses for this
study were conducted with SPSS version 20.0 (SPSS
Inc., Chicago, IL).
Results
In 2010, 3,609 subjects completed the spring NAR-
COMS update and supplemental surveys. Of those, 3,307
subjects also completed the PDDS, 3,338 completed
MSWS-12 and 3,557 completed the EQ-5D. Therefore,
of the 4,389 originally sent both surveys, a total of 3,044
NARCOMS registrants (69.4%) had complete data sets
and were included in this analysis. Characteristics of
these PwMS are depicted in Table 1. Most PwMS were
women, Caucasian, and on average, in their fifth decade
of life. Mean duration in time from initial MS diagnosis
was nearly 18 years, and 61.4% had received a disease-
Table 1 Characteristics of study population
Characteristics Patients (n = 3,044)
Age (mean, SD) 56.8 (9.9)





Duration (avg. years, SD) 17.9 (8.9)
DMD in previous 6 months (n, %) 1869 (61.4)*
Currently working/attending school (n, %) 1121 (36.8)










MSWS-12 Score (Mean, SD) 50.2 (33.7)
Median (Range) 52 (0–100)
Tertile 1 1138 (37.4%)
Tertile 2 763 (25.1%)
Tertile 3 1143 (37.5%)
EQ-5D (Mean, SD) 0.74 (0.18)
Median (Range) 0.78 (−0.04-1.0)
Floor (n, %) 0 (0%)
Ceiling (n, %) 404 (13.3%)
n = number of patients; PDDS = Patient Determined Disease Steps; MSWS-12 =
12-point Multiple Sclerosis Walking Scale; EQ-5D = EuroQol-5 Dimension Health
Status Index; SD = Standard Deviation; avg = average; IQR = interquartile range;
DMD = Disease-Modifying Drug; *Patients may have received ≥1 DMD in
previous 6 months.
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63% were not working or attending school. The mean
transformed MSWS-12 score for the entire population was
50.2 ± 33.7 (median and range = 52, 0–100), with PwMS
relatively evenly distributed among the three walking im-
pairment tertiles. The median PDDS of the population was
3, with at least three-quarters having a score of 5 or below.
EQ-5D index scores ranged from a minimum of −0.04 to a
maximum of 1.0 (0% and 13.3% at the floor and ceiling,
respectively) with a mean score of 0.74 ± 0.18 and a median
score (range) of 0.78 (−0.04-1.0). Moderately-strong corre-
lations between the EQ-5D and the PDDS and MSWS-12
were observed (Spearman’s r = −0.56 and −0.59, respect-
ively, p < 0.0001 for both).MCID estimates for EQ-5D index score within PDDS
score categories ranged from 0.065-0.158 (SEMs), 0.059-
0.142 (0.50 SDs) and 0.039-0.095 (0.33 SDs) (Table 2).
MCID estimates within MSWS-12 tertile categories
ranged from 0.068-0.098 (SEMs), 0.061-0.088 (0.50 SDs),
and 0.041-0.059 (0.33 SDs) (Table 3). Across both the
PDDS and tertiles of MSWS-12, MCID estimates
tended to get larger as disease severity worsened. Mean
weighted MCID estimates ranged from 0.050-0.084 for
both the PDDS and MSWS-12 tertiles.
Discussion
HRQoL assessments can be used by researchers in clinical
trials and clinicians and patients in real-world practice
settings to measure response to treatment and quantify
the impact of changes in disease severity; however, under-
standing what constitutes a minimally important change
on a HRQoL measure is critical for doing so. This is the
first study to calculate MCID estimates for the US-scored
EQ-5D health status index in PwMS. Our analysis
suggests the MCID for a population with MS likely falls
between the values of 0.050-0.084. However, our analysis
also suggests that the MCID varies by disease severity;
with higher estimates in those reporting greater disability
due to MS.
Prior studies have estimated MCID values for the US-
algorithm scored EQ-5D index in a variety of disease states
other than MS [17-20]. Luo and colleagues estimated EQ-
5D index scores in patients suffering leg ulcers, early
rheumatoid arthritis, back pain, and systemic sclerosis,
among others, using distribution-based approaches [17].
They estimated mean MCID estimates that were on the
lower end of our calculated ranges (0.040 for US-based
EQ-5D). In a study of intervertebral disk herniation,
anchor-based MCID estimates for the US-scored EQ-5D
ranged from 0.08-0.17 depending on the anchor used [20].
Le and colleagues found MCID estimates ranging between
0.05 and 0.08 when using anchor-based approaches and
0.04-0.10 using distribution-based approaches in a cohort
of patients suffering from post-traumatic stress disorder
[18]. Yet, another study conducted by Pickard and col-
leagues using a similar methodology to our own suggested
MCID estimates for US-based EQ-5D scores ranged from
0.07-0.09 in patients with cancer, and between 0.04 and
0.07 across various types of cancer [19]. While our range of
MCID estimates for the EQ-5D, 0.050-0.084, fall within
these previously reported ranges; these prior studies
suggest that a single MCID estimate for the EQ-5D does
not fit all.
A number of additional points should be considered when
interpreting our findings. First, given the cross-sectional
nature of the study and the exclusive use of distribution-
based methods, our MCID estimates are essentially
“between-patient” differences, rather than “within-patient”
Table 2 MCID estimates for EQ-5D based on PDDS subgroups
EQ-5D scores
PDDS* N Mean SD Median Min Max SEM 0.5 SD 0.33 SD
0 526 0.900 0.119 1.000 0.26 1.00 0.066 0.060 0.040
1 428 0.834 0.117 0.827 0.37 1.00 0.065 0.059 0.039
2 241 0.734 0.147 0.778 0.29 1.00 0.082 0.074 0.049
3 429 0.730 0.163 0.778 0.20 1.00 0.091 0.081 0.054
4 507 0.689 0.167 0.761 0.17 1.00 0.093 0.084 0.056
5 427 0.662 0.171 0.708 0.05 1.00 0.095 0.086 0.057
6 399 0.649 0.177 0.705 0.05 1.00 0.099 0.089 0.059
7 83 0.616 0.182 0.689 −0.04 0.85 0.101 0.091 0.061
8 4 0.463 0.284 0.410 0.18 0.85 0.158 0.142 0.095
Mean Weighted MCID 3044 — — — — — 0.084 0.076 0.051
N = number of patients; PDDS = Patient Determined Disease Steps; SEM = standard error of the measurement; SD = standard deviation.
*PDDS Score 0 =mild to no symptoms; 1 =mild disability; 2 = moderate disability; 3 = gait disability; 4 = early cane; 5 = late cane; 6 = bilateral support; 7 = wheel
chair/scooter; 8 = bedridden.
Kohn et al. Health and Quality of Life Outcomes 2014, 12:66 Page 4 of 5
http://www.hqlo.com/content/12/1/66changes over time. Therefore, our estimated MCIDs are
best suited for discriminating between patient groups, as
compared to defining responders to treatment. Second, the
population in the NARCOMS registry used for this study
may not be representative of all MS patients, particularly
those living outside of North America and those with PDDS
scores of 8. Moreover, NARCOMS data comes from semi-
annual surveys, and therefore, responses may be subject to
reporting or recall bias. However, despite these limitations
stemming from the registry’s design, it provides a unique
ability to look at a large (n > 3,000) population of PwMS
with varying degrees of disease severity (PDDS range: 0–8;
EQ-5D range: −0.04-1.0). This is important because MCID
estimates for the EQ-5D index score may vary to an import-
ant degree between persons in the same target cohort
[18,19]. In our analysis, the MCID was found to be largest
in PwMS having the most severe disease or walking impair-
ment, suggesting that patients perceive HRQoL differently
based the severity of their current health state. We recom-
mend using the MCID estimate that best matches the popu-
lation being studied/evaluated (i.e., a MCID of 0.08-0.09
may be more appropriate for patients with greater mobility
impairment; while a estimate of ~0.06 may be more suitable
for those less impaired). Third, in order to provide a range
of plausible EQ-5D MCIDs for PwMS based on disease se-
verity, we used the PDDS and MSWS-12 to define diseaseTable 3 MCID estimates for EQ-5D based on MSWS12 tertile s
EQ-5D s
MSWS12 tertiles N Mean SD Med
1 (0–33) 1138 0.861 0.123 0.83
2 (34–67) 763 0.718 0.154 0.77
3 (68–100) 1143 0.644 0.176 0.70
Mean Weighted MCID 3044 — — —
N = number of patients; MSWS12 Tertiles = Multiple Sclerosis Walking Scale coded iseverity categories. While we used the native ordinal scale
to categorize PwMS using the PDDS, it should be noted we
arbitrarily divided the MSWS-12 into equal tertiles based
upon score (with scores of 0 – 33 representing mild walking
impairment; 34 – 67 as moderate walking impairment; and
68 – 100 representing severe walking impairment). Next,
our analysis did not utilize an anchor-based approach,
which is often considered more desirable than the
distribution-based approaches we used for MCID estima-
tion [9,14]. Unfortunately, the lack of a true anchoring ques-
tion (one that allows for categorization of patients who
perceived only minimal improvement) in the NARCOMS
registry precluded the use of an anchor-based approach [9].
A common concern of distribution-based approaches is that
they assume data is normally distributed, and estimates can
be skewed when large floor or ceiling effects are present
[9,14]. However, this was less of a concern in our analysis,
since no PwMS were at the floor (lowest possible) EQ-5D
value (0% at −0.11) and only a small number were at the
ceiling (highest possible) EQ-5D score (13.3% at 1.00). A
final consideration for our analysis relates to its external
validity. Our use of a North American population and the
US population-based EQ-5D scoring algorithm likely means
our results are not highly externally valid to PwMS outside
the US. In fact, studies suggest EQ-5D index values and
MCID estimates using the US scoring algorithm varyubgroups
cores
ian Min Max SEM 0.5 SD 0.33 SD
3 0.29 1.00 0.068 0.061 0.041
8 0.20 1.00 0.086 0.077 0.051
8 −0.04 0.85 0.098 0.088 0.059
— — 0.084 0.075 0.050
nto tertiles; SEM = standard error of the measurement; SD = standard deviation.
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differences in the scaling properties of the EQ-5D from
country to country, as well as potential variation in popula-
tion characteristics [7,8,21]. For example, Johnson and col-
leagues [21] compared valuations of the same 42 EQ-5D
health states for US and UK populations, and found US
mean scores to be numerically higher than the UK for 39 of
the health states, with an average increase in score of 0.10
(p < 0.001) for US-based estimates compared to UK esti-
mates after adjusting for known predictors.
Conclusions
In conclusion, the MCID estimate calculated in this
study can aid researchers and clinicians when discrimin-
ating between patient groups for EQ-5D index scores of
PwMS. Our MCID range of 0.050-0.084 for EQ-5D was
within the range of MCID estimates of other disease
states. In general, patients who have severe disability had
higher MCIDs than patients who had mild-moderate
disability. Additional analysis to verify these EQ-5D
health status index MCID estimates in an independent
data set should be performed.
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